Drug class
Bile Sequestrants
Bile sequestrants, more formally termed bile acid sequestrants or bile acid resins, are a therapeutic class of nonabsorbable, positively charged polymeric agents. Read more about Bile Sequestrants
74 drugs in this class 34 manufacturers
Drugs in Bile Sequestrants
CHOLESTYRAMINE LIGHT (cholestyramine/aspartame)
CHOLESTYRAMINE LIGHT (cholestyramine/aspartame)
CHOLESTYRAMINE (cholestyramine (with sugar))
COLESEVELAM HCL
COLESTIPOL HCL
CHOLESTYRAMINE (cholestyramine (with sugar))
COLESEVELAM HCL
COLESEVELAM HCL
Bile sequestrants, more formally termed bile acid sequestrants or bile acid resins, are a therapeutic class of nonabsorbable, positively charged polymeric agents.
They exert their principal effect by binding negatively charged bile acids in the gastrointestinal tract to form insoluble complexes that are eliminated in the feces, thereby interrupting enterohepatic recirculation.
This depletion prompts the liver to convert endogenous cholesterol into new bile acids and upregulate hepatic low-density lipoprotein receptors, which lowers circulating low-density lipoprotein cholesterol.
Clinically, these agents are used primarily to treat hypercholesterolemia, improve glycemic control in type 2 diabetes mellitus, and manage chronic diarrhea caused by bile acid malabsorption.
-
nih.gov
Bile sequestrants, more formally termed bile acid sequestrants or bile acid resins, are a therapeutic class of nonabsorbable, positively charged polymeric agents They exert their principal effect by binding negatively charged bile acids in the gastrointestinal tract to form insoluble complexes that are eliminated in the feces, thereby interrupting enterohepatic recirculation
-
nih.gov
They exert their principal effect by binding negatively charged bile acids in the gastrointestinal tract to form insoluble complexes that are eliminated in the feces, thereby interrupting enterohepatic recirculation This depletion prompts the liver to convert endogenous cholesterol into new bile acids and upregulate hepatic low-density lipoprotein receptors, which lowers circulating low-density lipoprotein cholesterol Clinically, these agents are used primarily to treat hypercholesterolemia, imp...
-
nih.gov
This depletion prompts the liver to convert endogenous cholesterol into new bile acids and upregulate hepatic low-density lipoprotein receptors, which lowers circulating low-density lipoprotein cholesterol
-
nih.gov
Clinically, these agents are used primarily to treat hypercholesterolemia, improve glycemic control in type 2 diabetes mellitus, and manage chronic diarrhea caused by bile acid malabsorption
-
nih.gov
Clinically, these agents are used primarily to treat hypercholesterolemia, improve glycemic control in type 2 diabetes mellitus, and manage chronic diarrhea caused by bile acid malabsorption
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.